Insider Transactions in Q3 2022 at Akero Therapeutics, Inc. (AKRO)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
45,000
-9.7%
|
$1,440,000
$32.72 P/Share
|
|
Sep 30
2022
|
Timothy Rolph Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+3.99%
|
$260,000
$13.73 P/Share
|
|
Sep 13
2022
|
Timothy Rolph Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
22,500
-9.13%
|
$652,500
$29.18 P/Share
|
|
Sep 13
2022
|
William Richard White Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,500
-63.32%
|
$877,500
$27.15 P/Share
|
|
Sep 13
2022
|
William Richard White Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+46.81%
|
$227,500
$7.01 P/Share
|
|
Sep 13
2022
|
Catriona Yale Chief Development Officer |
SELL
Open market or private sale
|
Direct |
40,000
-17.94%
|
$1,080,000
$27.61 P/Share
|
|
Sep 13
2022
|
Andrew Cheng President and CEO |
SELL
Open market or private sale
|
Direct |
60,000
-8.38%
|
$1,620,000
$27.22 P/Share
|
|
Sep 13
2022
|
Andrew Cheng President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+13.95%
|
$0
$0.62 P/Share
|